THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.
Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.